Twist Bioscience (TWST) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.56
- Estimate
- -$0.18
- Surprise
- -212.4%
- Revenue (period 2026-06-30)
- $118.4M
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Twist Bioscience (TWST) reported a wider loss than forecast — diluted EPS of -$0.56 against the -$0.18 estimate (a 212.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates TWST Sell at 4.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -212.4% surprise compares with a -52.8% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Concentration risk — Product: synthetic DNA products
- Concentration risk — Supplier: single-source supplier
- Target reached (-25.5% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $126.85
- Price target
- $152.33
- Stop
- $117.97
- Upside to target
- +20.1%
Model outputs from TrendMatrix’s engine as of 2026-09-11 — shown for context, not personalized investment advice.
TWST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $7.87B
- P/E (fwd)
- -198.5
- 52-week range
- $23.30–$155.44
- Off 52-week high
- 18.4%
- RSI (14)
- 43
- Volume vs avg
- 0.81×
- Score today
- 4.5/10